Urovant Sciences ^Company

Urovant Sciences is a biopharmaceutical company that focuses on developing and selling innovative therapies for urologic conditions. Their main product candidate is vibegron, a beta-3 agonist that is being developed for overactive bladder, benign prostatic hyperplasia, and irritable bowel syndrome. They also have a second investigational product candidate, URO-902, which is a gene therapy for patients with overactive bladder symptoms. The company aims to improve the health of people through innovative treatments in psychiatry, oncology, urology, women's health, rare diseases, and cell & gene therapy.